Business Context and Reporting Period
This Form 8-K reports on the 2020 Annual Meeting of Stockholders held by Aeglea BioTherapeutics, Inc. on June 8, 2020. The registrant is an emerging growth company incorporated in Delaware, with its principal executive offices in Austin, Texas. The company's common stock trades on the Nasdaq Global Market under the symbol "AGLE."
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and does not contain financial performance data.
Material Changes and Corporate Actions
The primary material event reported is the outcome of the stockholder vote at the Annual Meeting. Two proposals were adopted:
- Election of Directors: Sandesh Mahatme and Suzanne Bruhn were elected as Class I directors to serve three-year terms expiring at the 2023 Annual Meeting.
- Ratification of Auditors: Stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2020.
Voting Results Summary
| Proposal | Shares For | Shares Against/Withheld | Broker Non-Votes |
|---|---|---|---|
| Election of Sandesh Mahatme | 17,305,542 | 3,978,746 (Withheld) | 4,076,092 |
| Election of Suzanne Bruhn | 18,334,519 | 2,949,769 (Withheld) | 4,076,092 |
| Ratification of PwC | 25,346,244 | 13,350 (Against) | 0 |
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of voting results.
Key Facts for Investor Verification
- Verify the tenure and background of the newly elected directors, Sandesh Mahatme and Suzanne Bruhn.
- Confirm the engagement terms and scope of work with the newly ratified auditor, PricewaterhouseCoopers LLP.
- Note the significant number of broker non-votes (over 4 million) regarding the director elections, which may indicate a large portion of shares held in street name where brokers lacked discretionary voting power.
- Review the company's most recent 10-K or 10-Q for financial metrics, as this 8-K contains no financial data.